Navigation Links
UC San Diego among first in nation to treat brain cancer with novel viral vector
Date:3/1/2012

UC San Diego Moores Cancer Center researchers and surgeons are among the first in the nation to treat patients with recurrent brain cancer by directly injecting an investigational viral vector into their tumor. The treatment is being developed by a local San Diego Company, Tocagen Inc.

"This clinical trial targets glioblastoma one of the deadliest forms of brain tumor," said principal investigator Santosh Kesari, MD, PhD, director of neuro-oncology in the Moores Cancer Center and in the Department of Neurosciences at the University of California, San Diego. "Clinical trials of investigational therapies such as this may lead to new treatment options for patients battling this deadly disease."

The current standard of care for a newly diagnosed, high-grade glioma includes surgically removing as much of the tumor as possible, followed by radiation therapy and chemotherapy. Despite these measures, the tumor usually recurs making this trial a high priority.

The trial is investigating the use of Toca 511 (vocimagene amiretrorepvec), for injection in combination with Toca FC (flucytosine), extended-release tablets. Toca 511 is a retroviral replicating vector (RRV) that is designed to deliver a cytosine deaminase (CD) gene selectively to cancer cells. After allowing time for the administered Toca 511 to spread through the cancerous tumor those cancer cells expressing the CD gene can convert flucytosine into the anti-cancer drug 5-fluorouracil (5-FU). In this study, patients receive cycles of oral Toca FC monthly for up to six months.

"This may provide a way to destroy the cancer cells without disrupting delicate neurocircuitry," explained surgeon scientist Clark Chen, MD, PhD, director of stereotactic and radiosurgery, UC San Diego Moores Cancer Center and an investigator on the study. Chen administered Toca 511 into the first patients who have participated in this clinical trial at UC San Diego. "We fused the patient's CT scan to their MRI and used neuro-navigation software to calculate exactly where in the tumor we needed to place the injection of Toca 511. The patients were given the injection and discharged from the hospital the day after the procedure."

Co-investigator Bob Carter, MD, PhD, chief of the Division of Neurosurgery at UC San Diego Medical Center and Moores Cancer Center, noted that this novel agent is the culmination of years of multi-disciplinary efforts. "Tocagen's investigational therapy, Toca 511 & Toca FC, is a representative example of the culmination of many technological advances that have come to pass during the last three decades," said Carter. "It is a convergence of years of hard work by dedicated public and private practitioners in many different fields including molecular biologists, basic scientists, virologists, physicists, mathematicians, surgeons, computer scientists, manufacturing experts, regulatory experts, and oncologists."

For Kesari, whose doctoral thesis focused on viral therapy for brain tumors, this has been a passion for 20 years. "I started this kind of research two decades ago, and to see a new technology like Toca 511 advance from bench to bedside completes the circle. This is the moment physician-researchers live for."

"This trial is an exciting realization of the ability to help our patients that comes from outstanding science combined with innovative thinking and the desire to deliver compassionate care," said William C. Mobley, MD, PhD, chair of the Department of Neurosciences at the UC San Diego School of Medicine. "At UC San Diego, we are intent upon transforming the care of patients with disorders of the brain."


'/>"/>

Contact: Kim Edwards
kecwards@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert  

Related medicine news :

1. UC San Diegos William C. Mobley recognized for contributions to Down syndrome
2. AAAS Pacific Division to convene joint session with world mummy scholars in San Diego
3. Study finds Filipino children in San Diego County at higher risk for Kawasaki disease
4. UC San Diego receives 2 major biomedical informatics grants
5. UC San Diego researchers identify factor boosting leukemias aggressiveness
6. La Jolla Institute to develop San Diegos first center for RNAi genomics research
7. UC San Diego partners with Mozambique University to deliver quality health care
8. UC San Diego researcher awarded $3.8 million for new path to breast cancer therapy
9. Type 1 diabetes research at UC San Diego gets $5 million boost
10. UC San Diegos Karin receives prestigious Harvey Prize
11. APA presents latest research on same-sex marriage at annual convention in San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UC San Diego among first in nation to treat brain cancer with novel viral vector
(Date:7/20/2017)... ... July 20, 2017 , ... A budget proposal to switch to ... - living - adjustment (COLA) is a bad deal for older and disabled Americans, ... index (CPI) would grow even more slowly than the conventional one that is currently ...
(Date:7/20/2017)... ... July 19, 2017 , ... Med Tech Solutions (MTS), a leading health care ... unit of Constellation Inc., a move that will help the company better serve its ... Louis, the acquisition is expected to help MTS expand its presence in ...
(Date:7/20/2017)... ... ... “Fidget”: a fun-filled, action-packed memoir of adventures. “Fidget” is the creation of ... who was a summa cum laude graduate of Gardner Webb University. She has won ... her retirement from public school, Lynn continued to pursue her love for music through ...
(Date:7/18/2017)... ... 2017 , ... The results of an international clinical trial, led in part by a UC ... of muscular dystrophy holds promise for a subgroup of patients. , In a paper just ... at 53 study sites in 18 countries describe the clinical benefit of using the drug ...
(Date:7/18/2017)... ... July 19, 2017 , ... ... it’s Corporate Social Responsibility Initiative in the prestigious CEO World Awards®. The ... organizational performance, new products and services, CEO case studies, corporate social responsibility, and ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... LAS VEGAS , July 13, 2017 It ... the United States is in the midst of ... Disease Control , since 1999, the number of overdose deaths ... , "resulting in over half a million dead from 2001 ... like codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a ...
(Date:7/12/2017)... -- Eli Lilly and Company (NYSE: LLY ) has ... pending patent litigation in the U.S. District Court for the ... Cialis ® (tadalafil) unit dose patent. This patent was ... of the agreement, Cialis exclusivity is now expected to end ... unit dose patent for Cialis is valid and infringed by ...
(Date:7/11/2017)... 11, 2017  Dr. Echenberg, founder of Echenberg Institute, is announcing a ... who suffer from painful intercourse and other painful pelvic pain conditions such ... to menopause. ... LLC ... Sarasota, Florida -based start-up company, VuVatech LLC, fills a void ...
Breaking Medicine Technology: